Previous Close | 1.7300 |
Open | 1.7100 |
Bid | 1.5700 x 400 |
Ask | 1.6400 x 400 |
Day's Range | 1.5520 - 1.7500 |
52 Week Range | 0.7700 - 14.0000 |
Volume | |
Avg. Volume | 6,418,484 |
Market Cap | 6.528M |
Beta (5Y Monthly) | 1.53 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.